The CPI1000+ cohort comprises data from seven tumor types (metastatic urothelial cancer [n = 387], malignant melanoma [n = 353], head and neck cancer [n = 107], non-small cell lung cancer [n = 76], renal cell carcinoma [RCC] [n = 51], colorectal cancer [n = 20], and breast cancer [n = 14]), treated with three classes of CPIs (anti-CTLA-4 [n = 155], anti-PD-1 [n = 432], and anti-PD-L1 [n = 421]) (Table S1). The gene discussed is CTLA4; the disease is renal cell carcinoma.